HIV-preventionGilead’s twice-yearly injectionGilead’s twice-yearly shot to prevent HIV succeeds in late-stage trialGilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.https://www.cnbc.com/2024/06/20/gilead-prep-lenacapavir-succeeds-in-phase-3-trial.htmlA twice-yearly injection offers 100% protection against HIV, study suggestsResearchers reported no infections in the young women and girls who got the shots in a study of about 5,000 in South Africa and Uganda.https://www.nbcnews.com/health/health-news/hiv-injection-twice-yearly-offers-protection-rcna163406An injectable HIV-prevention drug is highly effective — but wildly expensiveThrilled that lenacapavir, which is injected twice yearly, was highly effective in both gay men and women in clinical trials, HIV advocates worry it will prove too expensive for insurers.https://www.nbcnews.com/nbc-out/out-health-and-wellness/injectable-hiv-prevention-drug-lencapavir-rcna170778YeztugoFDA approves powerful HIV drug that nearly eliminated spread in clinical trialsThe twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.https://www.nbcnews.com/health/health-news/fda-hiv-prevention-drug-prep-lenacapavir-rcna208387
